Dr Robert Jotte speaks to ecancer at ASCO 2024 about results from the KRYSTAL-12 study - a phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harbouring a KRASG12C mutation.

He explains that this was a 450 patients study randomising 2:1 adagrasib to docetaxel.

Dr Jotte reports that the trial demonstrated an improvement in in progression-free survival and overall response rate with adagrasib over docetaxel as well as an improved intracranial response.